Autoplaque vs Cleerly LABS
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your clinical workflow prioritizes a workstation-based, local software solution for detailed, quantitative analysis of coronary plaques and stenoses from CT angiography images. This tool is ideal for clinicians who desire the ability to review and manually edit AI-generated segmentations of vessels, plaque, and lumen, ensuring precise control over the post-processing results within their existing computing environment.
View Autoplaque →Choose Cleerly LABS if…
Choose Cleerly LABS if your practice requires a comprehensive, cloud-based AI solution for personalized heart disease management, extending beyond just plaque quantification to include risk assessment and tracking disease progression over time. This web-based application is particularly well-suited for organizations seeking seamless integration with their PACS, RIS, and EHR systems, facilitating a broader, more integrated approach to cardiovascular care.
View Cleerly LABS →When choosing between Autoplaque and Cleerly LABS, physicians should consider their primary focus: detailed plaque characterization or a comprehensive, integrated heart disease management platform. Both are FDA-cleared AI-powered software tools designed for quantitative analysis of coronary plaques and luminal stenoses from CT angiography (CCTA) images, aiming to aid in heart attack risk prediction and treatment guidance.
Autoplaque, developed by Cedars-Sinai AIM, excels in providing AI-powered quantitative analysis of atherosclerotic plaque, including detection, characterization, and measurement of luminal stenoses. It is a workstation-based software, running on Windows or Mac platforms, and offers automated vessel, plaque, and lumen segmentation that clinicians can review and edit. This tool is best suited for physicians who prioritize in-depth, workstation-based analysis and direct control over segmentation for research or highly specialized clinical needs.
In contrast, Cleerly LABS offers a more comprehensive, web-based, AI-powered platform for analyzing CCTA images to detect, quantify, and characterize atherosclerosis and stenosis. A key practical difference is its cloud-based deployment, which, coupled with an on-site Cleerly Proxy for data transfer, allows for broader accessibility and integration with PACS, RIS, and EHR systems. Cleerly LABS also provides features like ischemia detection with its ISCHEMIA module, 3D visualization, personalized risk assessment, and the ability to track disease progression over time. Physicians seeking an integrated solution for personalized heart disease management, with features for tracking and potentially reducing the need for additional testing, may find Cleerly LABS more aligned with their practice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | Cleerly LABS |
|---|---|---|
| Pricing | Not disclosed | Per analysis |
| Deployment | Workstation-based software, runs on Windows or Mac computer platforms | Cloud-based (AWS), web-based application, with on-site Cleerly Proxy for data transfer. |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly LABSCleerly LABS (Tool B) is a cloud-based, web-based application, offering greater accessibility and potentially easier updates compared to Autoplaque's (Tool A) workstation-based deployment. Furthermore, Cleerly LABS's explicit integration with PACS, RIS, and EHR via a proxy suggests a more streamlined workflow within an enterprise clinical environment, enhancing overall usability.
Clinical Value
Cleerly LABSBoth tools are FDA-cleared and provide quantitative plaque and stenosis analysis for heart attack risk prediction. However, Cleerly LABS (Tool B) offers a more comprehensive approach by explicitly mentioning detailed plaque characterization (volume, type), ischemia detection via an additional module, personalized risk assessment, and tracking disease progression over time, suggesting broader clinical utility.
Pricing & Value
Cleerly LABSCleerly LABS (Tool B) provides transparent pricing information, including retail and discounted rates, allowing potential users to assess its cost-effectiveness. In contrast, Autoplaque (Tool A) has not disclosed its pricing, making it impossible to evaluate its value proposition.
Enterprise Readiness
Cleerly LABSCleerly LABS (Tool B) explicitly states it is HIPAA compliant and has a Business Associate Agreement (BAA), which are crucial for healthcare enterprise adoption. Its cloud-based deployment with an on-site proxy and integration capabilities with PACS, RIS, and EHR further enhance its readiness for large-scale clinical environments. Autoplaque (Tool A) lacks this explicit information.
Innovation
Cleerly LABSWhile both utilize AI for CCTA analysis, Cleerly LABS (Tool B) demonstrates a broader scope of innovation by including comprehensive plaque characterization (volume, type), an ischemia detection module, personalized risk assessment, and the ability to track disease progression. These features suggest a more advanced and holistic approach to cardiovascular disease management.
Support & Docs
TieNeither the provided structured facts nor a web search yielded specific, comparable details regarding the quality or availability of comprehensive support and documentation for both tools. While Cleerly (Tool B) as a commercial entity implies structured support, explicit comparative information is lacking for both.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | Cleerly LABS |
|---|---|---|
| Product Name | Autoplaque | Cleerly LABS |
| Developer/Company | Cedars-Sinai Medical Center: AIM | Cleerly |
| Core Analysis Focus | Quantitative analysis of coronary plaques and luminal stenoses from CT angiography images | Comprehensive analysis of coronary CT angiography (CCTA) to detect, quantify, and characterize atherosclerosis and stenosis |
| Key Feature (Segmentation/Visualization) | Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views | AI-powered CCTA image analysis; 3D visualization of coronary arteries |
| Key Feature (Clinical Aid/Progression) | Aiding in heart attack risk prediction and treatment guidance | Personalized heart disease risk assessment; Tracking disease progression over time |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and Cleerly LABS.
Frequently Asked Questions
More Comparisons
More matchups featuring Autoplaque or Cleerly LABS
Backers
Who funded each tool's parent company.